Dr. Funahashi on Enhanced Activity With Lenvatinib/Everolimus Combo in RCC

Yasuhiro Funahashi, MD
Published: Thursday, May 26, 2016

Yasuhiro Funahashi, MD, senior director, Eisai, discusses a study exploring the enhanced antitumor activity with the combination of lenvatinib (Lenvima) and everolimus (Afinitor) in patients with renal cell carcinoma (RCC).

Using human xenograft models, researchers found that the combination in this group of patients caused tumor regression and had no body weight loss. An immunohistochemistry analysis revealed a decrease of microvessel density in the lenvatinib and combination arms, as well as a decrease in the proportion of proliferative cells.

Results also showed that the treatment of lenvatinib in combination with everolimus caused significant antitumor effect in the xenograft models. These preclinical data provide a mechanism to support the significant clinical benefit observed in RCC with the combination of lenvatinib and everolimus.
SELECTED
LANGUAGE
Yasuhiro Funahashi, MD, senior director, Eisai, discusses a study exploring the enhanced antitumor activity with the combination of lenvatinib (Lenvima) and everolimus (Afinitor) in patients with renal cell carcinoma (RCC).

Using human xenograft models, researchers found that the combination in this group of patients caused tumor regression and had no body weight loss. An immunohistochemistry analysis revealed a decrease of microvessel density in the lenvatinib and combination arms, as well as a decrease in the proportion of proliferative cells.

Results also showed that the treatment of lenvatinib in combination with everolimus caused significant antitumor effect in the xenograft models. These preclinical data provide a mechanism to support the significant clinical benefit observed in RCC with the combination of lenvatinib and everolimus.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x